Argus Research has upgraded Zimmer Biomet Holdings Inc. (NYSE:ZBH) on launching new products and tuck-in M&A to build future growth drivers. One such driver is the ROSA system, which assists in ...
On Jan 21, we issued an updated research report on Zimmer Biomet Holdings, Inc. ZBH. The company continues to witness strength in the Asia Pacific (APAC), Europe, the Middle East and Africa (EMEA) ...
Zacks Investment Research on MSN
Pacira to divest iovera business to Zimmer Biomet in up to $140M deal
Pacira BioSciences PCRX is reshaping its business through an agreement to divest its iovera medical device franchise to ...
Zimmer Biomet Holdings (NYSE:ZBH) agreed to acquire Pacira BioSciences’ FDA cleared iovera pain relief device. The agreement includes a collaboration between the companies to advance the iovera ...
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopedic reconstructive products; sports ...
Medical device company Zimmer Biomet (NYSE:ZBH) in Q3 CY2025, with sales up 9.7% year on year to $2.00 billion. Its non-GAAP profit of $1.90 per share was 2.1% above analysts’ consensus estimates. Is ...
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported Q2 FY23 adjusted EPS of $1.82, in line with the consensus estimate. It posted Q2 sales of $1.870 billion, up 4.9% Y/Y (+6% constant currency). Revenues ...
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its second quarter earnings conference call will be webcast on Wednesday, August 5, 2026 at 8:30 a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results